Database Query Results : Berberine, ,

BBR, Berberine: Click to Expand ⟱

Features:

Berberine is a chemical found in some plants like European barberry, goldenseal, goldthread, Oregon grape, phellodendron, and tree turmeric. Berberine is a bitter-tasting and yellow-colored chemical.
Coptis (commonly referring to Coptidis Rhizoma, a traditional Chinese medicinal herb) contains bioactive alkaloids (most notably berberine and coptisine) that have been studied for their pharmacological effects—including their influence on reactive oxygen species (ROS) and related pathways.

– Berberine is known for its relatively low oral bioavailability, often cited at less than 1%. This low bioavailability is mainly due to poor intestinal absorption and active efflux by transport proteins such as P-glycoprotein.
– Despite the low bioavailability, berberine is still pharmacologically active, and its metabolites may also contribute to its overall effects.

• Effective Dosage in Studies
– Many clinical trials or preclinical studies use dosages in the range of 500 to 1500 mg per day, typically administered in divided doses.
– Therefore, to obtain a bioactive dose of berberine, supplementation in a standardized extract form is necessary.

-IC50 in cancer cell lines: Approximately 10–100 µM (commonly around 20–50 µM in many models)
-IC50 in normal cell lines: Generally higher (often above 100 µM), although this can vary with cell type
- In vivo studies: Dosing regimens in animal models generally range from about 50 to 200 mg/kg
- very effective AChE inhibitor (Alzheimers)
- Berberine may enhance the effects of blood-thinning medications like warfarin and aspirin.

-Note half-life reports vary 2.5-90hrs?.
-low solubility of apigenin in water : BioAv
Pathways:
- induce ROS production
- ROS↑ related: MMP↓(ΔΨm), ER Stress↑, Ca+2↑, Cyt‑c↑, Caspases↑, DNA damage↑, UPR↑, cl-PARP↑, HSP↓
- Lowers AntiOxidant defense in Cancer Cells: NRF2↓, GSH↓
- Raises AntiOxidant defense in Normal Cells: NRF2↑, SOD↑, GSH↑, Catalase↑,
- lowers Inflammation : NF-kB↓, COX2↓, p38↓, Pro-Inflammatory Cytokines : IL-1β↓, TNF-α↓, IL-6↓, IL-8↓
- PI3K/AKT(Inhibition), JAK/STATs, Wnt/β-catenin, AMPK, MAPK/ERK, and JNK.
- inhibit Growth/Metastases : , MMPs↓, MMP2↓, MMP9↓, IGF-1↓, uPA↓, VEGF↓, ROCK1↓, FAK↓, RhoA↓, NF-κB↓, CXCR4↓, TGF-β↓, α-SMA↓, ERK↓
- reactivate genes thereby inhibiting cancer cell growth : HDAC↓, DNMT1↓, EZH2↓, P53↑, HSP↓
- cause Cell cycle arrest : TumCCA↑, cyclin D1↓, cyclin E↓, CDK2↓, CDK4↓, CDK6↓,
- inhibits Migration/Invasion : TumCMig↓, TumCI↓, FAK↓, ERK↓,
- inhibits glycolysis /Warburg Effect and ATP depletion : HIF-1α↓, PKM2↓, cMyc↓, GLUT1↓, LDH↓, LDHA↓, HK2↓, PFKs↓, PDKs↓, Glucose↓, GlucoseCon↓
- inhibits angiogenesis↓ : VEGF↓, HIF-1α↓, Notch↓, FGF↓, PDGF↓, EGFR↓, Integrins↓,
- inhibits Cancer Stem Cells : CSC↓, Hh↓, GLi1↓, CD133↓, β-catenin↓, n-myc↓, sox2↓, notch2↓, nestin↓, OCT4↓,
- Others: PI3K↓, AKT↓, JAK↓, STAT↓, Wnt↓, β-catenin↓, AMPK↓, α↓, ERK↓, JNK,
- Synergies: chemo-sensitization, chemoProtective, RadioSensitizer, RadioProtective, Others(review target notes), Neuroprotective, Cognitive, Renoprotection, Hepatoprotective, CardioProtective,
- Selectivity: Cancer Cells vs Normal Cells

Rank	Pathway / Target Axis	Direction	Primary Effect	Notes / Cancer Relevance	Ref
1	AMPK → mTOR axis	↑ AMPK / ↓ mTOR signaling	Metabolic stress + growth suppression	In vivo/in vitro colon tumorigenesis model: berberine activates AMPK, inhibits mTOR signaling and reduces proliferation/tumorigenesis, growth suppression, autophagy, HIF-1α ↓, glycolysis ↓, berberine’s known mitochondrial/energetic effects	(ref)
2	Mitochondrial dysfunction / ROS generation	↑ ROS / mitochondrial stress	Upstream metabolic trigger	Berberine inhibits mitochondrial function, increases ROS, and contributes to AMPK activation and downstream apoptosis	(ref)
3	Mitochondrial apoptosis (cytochrome c release)	↑ cytochrome c release	Intrinsic death signaling	Oral cancer model: berberine reduces mitochondrial membrane potential, releases cytochrome c, activates caspase-3	(ref)
4	Intrinsic apoptosis (caspase-3 activation)	↑ caspase-3 activation	Programmed cell death	Same oral cancer study documents caspase-3 activation as a key execution marker	(ref)
5	NF-κB signaling (p65 activation)	↓ NF-κB activation	Reduced pro-survival transcription	Colon cancer model reports inhibition of p65 phosphorylation; interpreted as secondary to metabolic/redox stress	(ref)
6	Cell cycle control	↑ G1 arrest	Proliferation blockade	Prostate cancer model: berberine induces G1-phase cell cycle arrest and caspase-3–dependent apoptosis	(ref)
7	Hypoxia / glycolysis signaling (HIF-1α)	↓ HIF-1α protein	Warburg / glycolysis suppression	Berberine suppresses mTOR and reduces HIF-1α protein expression downstream of AMPK activation	(ref)
8	Angiogenesis signaling (HIF-1α → VEGF axis)	↓ VEGF signaling	Reduced vascular support	Lung cancer study: berberine suppresses VEGF signaling alongside HIF-1α inhibition	(ref)
9	PI3K–AKT–mTOR signaling	↓ PI3K / AKT / mTOR	Survival pathway suppression	Gastric cancer paper: berberine represses PI3K/AKT/mTOR signaling and improves chemosensitivity	(ref)
10	Migration / invasion programs	↓ migration & invasion	Anti-metastatic phenotype	Tongue SCC model: berberine suppresses migration and invasion with associated signaling changes	(ref)
11	Telomerase (hTERT) / immortalization axis	↓ hTERT-related signaling	Reduced proliferative capacity	Lung cancer study includes AP-2/hTERT regulatory axis modulation by berberine	(ref)
12	In vivo tumor suppression	↓ tumorigenesis	Demonstrated anti-tumor effect	Colon tumorigenesis model confirms reduced proliferation and tumor burden with berberine	(ref)

Scientific Papers found: Click to Expand⟱

2698-

BBR,

A gene expression signature-based approach reveals the mechanisms of action of the Chinese herbal medicine berberine

Analysis,

BC,

MDA-MB-231

"highlight2" >HDAC↓, "highlight2" >Akt↓, "highlight2" >mTOR↓, "highlight2" >ER Stress↑, "highlight2" >TumAuto↑, "highlight2" >AMPK↑, "highlight2" >mTOR∅, "highlight2" >HDAC∅, "highlight2" >ac‑α-tubulin↑,

2712-

BBR,

Suppression of colon cancer growth by berberine mediated by the intestinal microbiota and the suppression of DNA methyltransferases (DNMTs)

in-vitro,

Colon,

HT29

in-vivo,

NA,

"highlight2" >TumCG↓, "highlight2" >GutMicro↑, "highlight2" >other↝, "highlight2" >IL10↓, "highlight2" >cMyc↓, "highlight2" >DNMT1↓, "highlight2" >DNMTs↓,

2711-

BBR,

Berberine inhibits the progression of breast cancer by regulating METTL3-mediated m6A modification of FGF7 mRNA

in-vitro,

BC,

MCF-7

0, 20, 40, and 60 μM) of BBR for 48 h

in-vitro,

BC,

MDA-MB-231

in-vivo,

NA,

"highlight2" >TumCP↓, "highlight2" >TumCI↓, "highlight2" >TumCMig↓, "highlight2" >Apoptosis↑, "highlight2" >FGF↓, "highlight2" >IGFBP3↑,

2710-

BBR,

Berberine inhibits the Warburg effect through TET3/miR-145/HK2 pathways in ovarian cancer cells

in-vitro,

Ovarian,

SKOV3

"highlight2" >Warburg↓, "highlight2" >miR-145↑, "highlight2" >HK2↓, "highlight2" >TET3↑, "highlight2" >Glycolysis↓, "highlight2" >PKM2↓, "highlight2" >GLUT1↓, "highlight2" >LDH↓, "highlight2" >PFK2↓, "highlight2" >PDK1↓,

2709-

BBR,

Berberine inhibits the glycolysis and proliferation of hepatocellular carcinoma cells by down-regulating HIF-1α

in-vitro,

HCC,

HepG2

0, 50, 100, or 200 μmol/

"highlight2" >TumCP↓, "highlight2" >TumCMig↓, "highlight2" >TumCI↓, "highlight2" >Apoptosis↑, "highlight2" >Glycolysis↓, "highlight2" >Hif1a↓, "highlight2" >GLUT1↓, "highlight2" >HK2↓, "highlight2" >PKM2↓, "highlight2" >LDHA↓,

2708-

BBR,

Berberine decelerates glucose metabolism via suppression of mTOR‑dependent HIF‑1α protein synthesis in colon cancer cells

in-vitro,

CRC,

HCT116

 0, 6.25, 12.5, 25, 50 and 100 µM of berberine for 24 or 15 h

"highlight2" >TumCG↓, "highlight2" >GlucoseCon↓, "highlight2" >GLUT1↓, "highlight2" >LDHA↓, "highlight2" >HK2↓, "highlight2" >Hif1a↓, "highlight2" >mTOR↓, "highlight2" >Glycolysis↓,

2707-

BBR,

Berberine exerts its antineoplastic effects by reversing the Warburg effect via downregulation of the Akt/mTOR/GLUT1 signaling pathway

in-vitro,

Liver,

HepG2

concentrations >25 µM after 48 h

in-vitro,

BC,

MCF-7

"highlight2" >GLUT1↓, "highlight2" >Akt↓, "highlight2" >mTOR↓, "highlight2" >ATP↓, "highlight2" >GlucoseCon↓, "highlight2" >TumCP↓, "highlight2" >Warburg↓, "highlight2" >selectivity↑, "highlight2" >TumCCA↑, "highlight2" >Glycolysis↓,

2706-

BBR,

Berberine Inhibits Growth of Liver Cancer Cells by Suppressing Glutamine Uptake

in-vitro,

HCC,

Hep3B

 50, 75, 100 and 125 μM

in-vitro,

HCC,

Bel-7402

in-vivo,

NA,

"highlight2" >TumCP↓, "highlight2" >glut↓, "highlight2" >SLC12A5↓, "highlight2" >cMyc↓, "highlight2" >GLS↓,

2705-

BBR,

Mechanism underlying berberine's effects on HSP70/TNFα under heat stress: Correlation with the TATA boxes

in-vivo,

Nor,

male ICR mice (8-10 weeks old, weighing 21-23 g)

in-vitro,

Nor,

PC12

"highlight2" >HSP70/HSPA5↓, "highlight2" >TNF-α↓,

2704-

BBR,

Inhibitory Effect of Berberine on Zeste Homolog 2 (Ezh2) Enhancement in Human Esophageal Cell Lines

in-vitro,

ESCC,

KYSE450

"highlight2" >EZH2↓, "highlight2" >AXL↓,

2703-

BBR,

CUR,

SFN,

UA,

GamB

Naturally occurring anti-cancer agents targeting EZH2

Review,

Var,

"highlight2" >EZH2↓,

2702-

BBR,

The enhancement of combination of berberine and metformin in inhibition of DNMT1 gene expression through interplay of SP1 and PDPK1

in-vitro,

Lung,

A549

in-vitro,

Lung,

H1975

"highlight2" >TumCG↓, "highlight2" >MAPK↓, "highlight2" >FOXO3↑, "highlight2" >TumCCA↑, "highlight2" >TumCMig↓, "highlight2" >TumCI↓, "highlight2" >Sp1/3/4↓, "highlight2" >PDK1↓, "highlight2" >DNMT1↓, "highlight2" >eff↑,

2701-

BBR,

Berberine Inhibits KLF4 Promoter Methylation and Ferroptosis to Ameliorate Diabetic Nephropathy in Mice

in-vivo,

Diabetic,

MICE

"highlight2" >*Inflam↓, "highlight2" >*antiOx↑, "highlight2" >*Ferroptosis↓, "highlight2" >*RenoP↑, "highlight2" >*DNMT1↓, "highlight2" >*DNMTs↓, "highlight2" >*KLF4↑,

2700-

BBR,

Cell-specific pattern of berberine pleiotropic effects on different human cell lines

in-vitro,

GBM,

U343

in-vitro,

GBM,

MIA PaCa-2

in-vitro,

Nor,

HDFa

"highlight2" >selectivity↑, "highlight2" >TumCCA↑, "highlight2" >Casp3↑, "highlight2" >TumCI↓, "highlight2" >TumCMig↓, "highlight2" >N-cadherin?, "highlight2" >DNMT1↑,

2699-

BBR,

Plant Isoquinoline Alkaloid Berberine Exhibits Chromatin Remodeling by Modulation of Histone Deacetylase To Induce Growth Arrest and Apoptosis in the A549 Cell Line

in-vitro,

Lung,

A549

"highlight2" >HDAC↓, "highlight2" >TumCCA↑, "highlight2" >TNF-α↓, "highlight2" >COX2↓, "highlight2" >MMP2↓, "highlight2" >MMP9↓, "highlight2" >P21↑, "highlight2" >P53↑, "highlight2" >Casp↑, "highlight2" >ac‑H3↑, "highlight2" >ac‑H4↑, "highlight2" >ROS↑, "highlight2" >MMP↓,

2713-

BBR,

Berberine improved the microbiota in lung tissue of colon cancer and reversed the bronchial epithelial cell changes caused by cancer cells

in-vitro,

Nor,

BEAS-2B

Thirty-six BALB/c nude mice

"highlight2" >*GutMicro↑, "highlight2" >*IL6↑, "highlight2" >*IL10↑, "highlight2" >*IL17↑, "highlight2" >*IFN-γ↑, "highlight2" >PDGF↓, "highlight2" >*RAD51↓,

2697-

BBR,

Structural exploration of common pharmacophore based berberine derivatives as novel histone deacetylase inhibitor targeting HDACs enzymes

Analysis,

Var,

"highlight2" >HDAC↓,

2696-

BBR,

Berberine regulates proliferation, collagen synthesis and cytokine secretion of cardiac fibroblasts via AMPK-mTOR-p70S6K signaling pathway

in-vivo,

Nor,

 1-3 day-old SD rats

"highlight2" >*α-SMA↓, "highlight2" >*TGF-β1↓, "highlight2" >*IL10↑, "highlight2" >*p‑AMPK↑, "highlight2" >*p‑mTOR↓, "highlight2" >*P70S6K↓, "highlight2" >*cardioP↑,

2695-

BBR,

The effects of Berberis vulgaris consumption on plasma levels of IGF-1, IGFBPs, PPAR-γ and the expression of angiogenic genes in women with benign breast disease: a randomized controlled clinical trial

Trial,

BC,

85 eligible patients diagnosed with benign breast disease.

"highlight2" >IGF-1↓, "highlight2" >PPARγ↓, "highlight2" >VEGF↓, "highlight2" >Hif1a↓, "highlight2" >angioG↓,

2694-

BBR,

Berberine down-regulates IL-8 expression through inhibition of the EGFR/MEK/ERK pathway in triple-negative breast cancer cells

in-vitro,

BC,

"highlight2" >IL8↓, "highlight2" >TumCI↓, "highlight2" >EGFR↓, "highlight2" >MEK↓, "highlight2" >ERK↓, "highlight2" >TGF-β1↓, "highlight2" >VEGF↓,

2693-

BBR,

Antitumor Effects of Berberine on Gliomas via Inactivation of Caspase-1-Mediated IL-1β and IL-18 Release

in-vitro,

GBM,

U251

in-vitro,

GBM,

U87MG

"highlight2" >Casp1↓, "highlight2" >ERK↓, "highlight2" >IL1β↓, "highlight2" >IL18↓, "highlight2" >EMT↑,

2692-

BBR,

Berberine affects osteosarcoma via downregulating the caspase-1/IL-1β signaling axis

in-vitro,

OS,

MG63

in-vitro,

OS,

SaOS2

in-vivo,

NA,

mice

"highlight2" >Casp1↓, "highlight2" >IL1β↓, "highlight2" >TumCG↓, "highlight2" >Dose↝, "highlight2" >Apoptosis↑, "highlight2" >Inflam↓,

2691-

BBR,

Berberine induces FasL-related apoptosis through p38 activation in KB human oral cancer cells

in-vitro,

Oral,

"highlight2" >tumCV↓, "highlight2" >DNAdam↑, "highlight2" >Casp3↑, "highlight2" >Casp7↑, "highlight2" >FasL↑, "highlight2" >Casp8↑, "highlight2" >Casp9↑, "highlight2" >PARP↑, "highlight2" >BAX↑, "highlight2" >BAD↑, "highlight2" >APAF1↑, "highlight2" >MMP2↓, "highlight2" >MMP9↓, "highlight2" >p‑p38↑, "highlight2" >ERK↑, "highlight2" >MAPK↑,

2690-

BBR,

Berberine Differentially Modulates the Activities of ERK, p38 MAPK, and JNK to Suppress Th17 and Th1 T Cell Differentiation in Type 1 Diabetic Mice

in-vivo,

Diabetic,

berberine (Sigma, 200 mg/kg body weight), by gavage, daily for 2 weeks

11-week-old female NOD mice

"highlight2" >*Inflam↓, "highlight2" >*Th17↓, "highlight2" >*Th1 response↓, "highlight2" >*ERK↑, "highlight2" >*p38↓, "highlight2" >*JNK↓, "highlight2" >*STAT1↓, "highlight2" >*STAT4↓, "highlight2" >*MAPK↓,

2689-

BBR,

Berberine protects against glutamate-induced oxidative stress and apoptosis in PC12 and N2a cells

in-vitro,

Nor,

PC12

in-vitro,

AD,

in-vitro,

Stroke,

"highlight2" >*ROS↓, "highlight2" >*lipid-P↓, "highlight2" >*DNAdam↓, "highlight2" >*GSH↑, "highlight2" >*SOD↑, "highlight2" >*eff↑, "highlight2" >*cl‑Casp3↓, "highlight2" >*BAX↓, "highlight2" >*neuroP↑, "highlight2" >*Dose↝, "highlight2" >*Ca+2↓,

2686-

BBR,

Effects of resveratrol, curcumin, berberine and other nutraceuticals on aging, cancer development, cancer stem cells and microRNAs

Review,

Nor,

"highlight2" >Inflam↓, "highlight2" >IL6↓, "highlight2" >MCP1↓, "highlight2" >COX2↓, "highlight2" >PGE2↓, "highlight2" >MMP2↓, "highlight2" >MMP9↓, "highlight2" >DNAdam↑, "highlight2" >eff↝, "highlight2" >Telomerase↓, "highlight2" >Bcl-2↓, "highlight2" >AMPK↑, "highlight2" >ROS↑, "highlight2" >MMP↓, "highlight2" >ATP↓, "highlight2" >p‑mTORC1↓, "highlight2" >p‑S6K↓, "highlight2" >ERK↓, "highlight2" >PI3K↓, "highlight2" >PTEN↑, "highlight2" >Akt↓, "highlight2" >Raf↓, "highlight2" >MEK↓, "highlight2" >Dose↓, "highlight2" >Dose↑, "highlight2" >selectivity↑, "highlight2" >TumCCA↑, "highlight2" >eff↑, "highlight2" >EGFR↓, "highlight2" >Glycolysis↓, "highlight2" >Dose?, "highlight2" >p27↑, "highlight2" >CDK2↓, "highlight2" >CDK4↓, "highlight2" >cycD1/CCND1↓, "highlight2" >cycE/CCNE↓, "highlight2" >Bax:Bcl2↑, "highlight2" >Casp3↑, "highlight2" >Casp9↑, "highlight2" >VEGFR2↓, "highlight2" >ChemoSen↑, "highlight2" >eff↑, "highlight2" >eff↑, "highlight2" >PGE2↓, "highlight2" >JAK2↓, "highlight2" >STAT3↓, "highlight2" >CXCR4↓, "highlight2" >CCR7↓, "highlight2" >uPA↓, "highlight2" >CSCs↓, "highlight2" >EMT↓, "highlight2" >Diff↓, "highlight2" >CD133↓, "highlight2" >Nestin↓, "highlight2" >n-MYC↓, "highlight2" >NOTCH↓, "highlight2" >SOX2↓, "highlight2" >Hif1a↓, "highlight2" >VEGF↓, "highlight2" >RadioS↑,

2685-

BBR,

Berberine induces neuronal differentiation through inhibition of cancer stemness and epithelial-mesenchymal transition in neuroblastoma cells

in-vitro,

neuroblastoma,

"highlight2" >CSCs↓, "highlight2" >CD133↓, "highlight2" >β-catenin/ZEB1↓, "highlight2" >n-MYC↓, "highlight2" >SOX2↓, "highlight2" >NOTCH2↓, "highlight2" >Nestin↓, "highlight2" >TumCCA↑, "highlight2" >TumCP↓, "highlight2" >CDK1↓, "highlight2" >Cyc↓, "highlight2" >Apoptosis↑, "highlight2" >Bax:Bcl2↑, "highlight2" >NCAM↓, "highlight2" >MMP2↓, "highlight2" >MMP9↓, "highlight2" >*Smad1↑, "highlight2" >*HSP70/HSPA5↑, "highlight2" >*LAMs↑,

2684-

BBR,

Berberine is a Novel Mitochondrial Calcium Uniporter Inhibitor that Disrupts MCU‐EMRE Assembly

in-vivo,

Nor,

mice

"highlight2" >*MCU↓, "highlight2" >*mt-Ca+2↓, "highlight2" >*cardioP↑,

2683-

BBR,

Berberine reduces endoplasmic reticulum stress and improves insulin signal transduction in Hep G2 cells

in-vitro,

Liver,

HepG2

"highlight2" >JNK↓, "highlight2" >p‑PERK↓, "highlight2" >p‑eIF2α↓, "highlight2" >*ER Stress↓,

3833-

BBR,

Traditional Chinese Medicine: Role in Reducing β-Amyloid, Apoptosis, Autophagy, Neuroinflammation, Oxidative Stress, and Mitochondrial Dysfunction of Alzheimer’s Disease

Review,

AD,

"highlight2" >*cardioP↑, "highlight2" >*neuroP↑, "highlight2" >*memory↑, "highlight2" >*Aβ↓,

5182-

BBR,

Berberine suppresses in vitro migration and invasion of human SCC-4 tongue squamous cancer cells through the inhibitions of FAK, IKK, NF-κB, u-PA and MMP-2 and -9

in-vitro,

SCC,

SCC4

"highlight2" >TumCMig↓, "highlight2" >TumCI↓, "highlight2" >p‑JNK↝, "highlight2" >p‑ERK↝, "highlight2" >p‑p38↝, "highlight2" >IKKα↝, "highlight2" >NF-kB↝, "highlight2" >MMP2↓, "highlight2" >MMP9↓,

5181-

BBR,

Cisplatin,

Berberine Improves Chemo-Sensitivity to Cisplatin by Enhancing Cell Apoptosis and Repressing PI3K/AKT/mTOR Signaling Pathway in Gastric Cancer

in-vitro,

GC,

SGC-7901

in-vitro,

GC,

BGC-823

"highlight2" >tumCV↓, "highlight2" >MDR1↓, "highlight2" >ChemoSen↑, "highlight2" >PI3K↓, "highlight2" >Akt↓, "highlight2" >mTOR↓,

5180-

BBR,

Berberine Targets AP-2/hTERT, NF-κB/COX-2, HIF-1α/VEGF and Cytochrome-c/Caspase Signaling to Suppress Human Cancer Cell Growth

in-vitro,

NSCLC,

100 µM BBR

"highlight2" >TumCMig↓, "highlight2" >TumCP↓, "highlight2" >Apoptosis↑, "highlight2" >TFAP2A↓, "highlight2" >hTERT/TERT↓, "highlight2" >NF-kB↓, "highlight2" >COX2↓, "highlight2" >Hif1a↓, "highlight2" >VEGF↓, "highlight2" >Akt↓, "highlight2" >p‑ERK↓, "highlight2" >Cyt‑c↑, "highlight2" >cl‑Casp↑, "highlight2" >cl‑PARP↑, "highlight2" >PI3K↓, "highlight2" >Akt↓, "highlight2" >Raf↓, "highlight2" >MEK↓, "highlight2" >ERK↓,

5179-

BBR,

Regulation of Cell Signaling Pathways by Berberine in Different Cancers: Searching for Missing Pieces of an Incomplete Jig-Saw Puzzle for an Effective Cancer Therapy

Review,

Var,

"highlight2" >AMPK↑, "highlight2" >Casp3↑, "highlight2" >cl‑PARP↑, "highlight2" >Mcl-1↓, "highlight2" >cFLIP↓, "highlight2" >β-catenin/ZEB1↓, "highlight2" >Wnt↓, "highlight2" >STAT3↓, "highlight2" >mTOR↓, "highlight2" >Hif1a↓, "highlight2" >NF-kB↓, "highlight2" >SIRT1↑, "highlight2" >DNMT1↓, "highlight2" >DNMT3A↓, "highlight2" >miR-29b↓, "highlight2" >IGFBP1↑, "highlight2" >eff↑, "highlight2" >chemoPv↑, "highlight2" >BioAv↓,

5178-

BBR,

Berberine, a natural product, induces G1-phase cell cycle arrest and caspase-3-dependent apoptosis in human prostate carcinoma cells

in-vitro,

Pca,

DU145

in-vitro,

Pca,

PC3

"highlight2" >TumCP↑, "highlight2" >TumCCA↑, "highlight2" >cycD1/CCND1↓, "highlight2" >cycE/CCNE↓, "highlight2" >CDK2↓, "highlight2" >CDK4↓, "highlight2" >CDK6↓, "highlight2" >P21↑, "highlight2" >p27↑, "highlight2" >Apoptosis↑, "highlight2" >Bax:Bcl2↑, "highlight2" >MMP↓, "highlight2" >Casp9↑, "highlight2" >Casp3↑, "highlight2" >PARP↑, "highlight2" >DNAdam↑, "highlight2" >selectivity↑, "highlight2" >Cyt‑c↑,

5177-

BBR,

Berberine induces apoptosis in human HSC-3 oral cancer cells via simultaneous activation of the death receptor-mediated and mitochondrial pathway

in-vitro,

Oral,

HMC3

"highlight2" >TumCCA↑, "highlight2" >Apoptosis↑, "highlight2" >TumCG↓, "highlight2" >Casp3↑, "highlight2" >TumCCA↑, "highlight2" >ROS↑, "highlight2" >Ca+2↑, "highlight2" >MMP↓, "highlight2" >ER Stress↑, "highlight2" >Cyt‑c↑,

5176-

BBR,

Berberine regulates AMP-activated protein kinase signaling pathways and inhibits colon tumorigenesis in mice

vitro+vivo,

CRC,

HCT116

mice

in-vitro,

CRC,

SW480

in-vitro,

CRC,

LoVo

"highlight2" >TumVol↓, "highlight2" >Ki-67↓, "highlight2" >COX2↓, "highlight2" >AMPK↑, "highlight2" >mTOR↓, "highlight2" >NF-kB↓, "highlight2" >cycD1/CCND1↓, "highlight2" >survivin↓, "highlight2" >P53↑, "highlight2" >cl‑Casp3↑, "highlight2" >TumCP↓, "highlight2" >Inflam↓, "highlight2" >COX2↓, "highlight2" >ACC↑,

4658-

BBR,

Berberine Suppresses Stemness and Tumorigenicity of Colorectal Cancer Stem-Like Cells by Inhibiting m6A Methylation

in-vitro,

CRC,

HCT116

in-vitro,

CRC,

HT29

"highlight2" >CSCs↓, "highlight2" >TumCP↓, "highlight2" >cycD1/CCND1↓, "highlight2" >p27↑, "highlight2" >P21↑, "highlight2" >TumCCA↑, "highlight2" >Apoptosis↑, "highlight2" >ChemoSen↑, "highlight2" >β-catenin/ZEB1↓, "highlight2" >FTO↑, "highlight2" >CD44↓, "highlight2" >CD133↓, "highlight2" >ChemoSen↑,

4340-

BBR,

Agonist-dependent differential effects of berberine in human platelet aggregation

Human,

NA,

prepared from blood of normal human volunteers

"highlight2" >*AntiAg↑, "highlight2" >*other?,

4300-

BBR,

Effect of berberine on cognitive function and β-amyloid precursor protein in Alzheimer’s disease models: a systematic review and meta-analysis

Review,

AD,

"highlight2" >*APP↓, "highlight2" >*cognitive↑, "highlight2" >*Aβ↓, "highlight2" >*BACE↓, "highlight2" >*tau?,

4299-

BBR,

Berberine attenuates cognitive impairment and ameliorates tau hyperphosphorylation by limiting the self-perpetuating pathogenic cycle between NF-κB signaling, oxidative stress and neuroinflammation

in-vivo,

AD,

AD mice

"highlight2" >*memory↑, "highlight2" >*p‑tau↓, "highlight2" >*NF-kB↓, "highlight2" >*GSH↑, "highlight2" >*lipid-P↓, "highlight2" >*cognitive↑, "highlight2" >*ROS↓, "highlight2" >*Inflam↓,

4298-

BBR,

Berberine mitigates cognitive decline in an Alzheimer’s Disease Mouse Model by targeting both tau hyperphosphorylation and autophagic clearance

in-vivo,

AD,

in drinking water at 100 mg/kg/day, and lasted four months

3×Tg AD mice

"highlight2" >*cognitive↑, "highlight2" >*p‑tau↓, "highlight2" >*GSK‐3β↓, "highlight2" >*PP2A↑,

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 117

Pathway results for Effect on Cancer / Diseased Cells:

Pathway results for Effect on Normal Cells:

Redox & Oxidative Stress ⓘ

antiOx?, 1, antiOx↓, 1, antiOx↑, 11, Catalase↑, 2, Ferroptosis↓, 2, GPx↑, 2, GSH↑, 3, HO-1↑, 2, lipid-P↓, 6, MDA↓, 3, NADPH/NADP+↑, 1, NRF2↑, 2, RNS↓, 1, ROS↓, 14, ROS∅, 1, SOD↑, 3,

Metal & Cofactor Biology ⓘ

FTH1↑, 1, TfR1/CD71↓, 1,

Mitochondria & Bioenergetics ⓘ

ATP↓, 1, MMP∅, 1, OCR↓, 1,

Core Metabolism/Glycolysis ⓘ

ALAT↓, 1, AMPK↓, 1, AMPK↑, 2, p‑AMPK↑, 1, CREB↑, 1, glucoNG↓, 1, Glycolysis↑, 1, LDL↓, 2, MCU↓, 1, NH3↑, 1, PKM2↓, 1, PPARγ↑, 1,

Cell Death ⓘ

Akt↓, 1, Akt↑, 3, p‑Akt↑, 1, Apoptosis↓, 3, Apoptosis∅, 1, BAX↓, 1, cl‑Casp3↓, 1, Ferroptosis↓, 2, JNK↓, 3, MAPK↓, 3, p38↓, 2,

Transcription & Epigenetics ⓘ

other?, 1,

Protein Folding & ER Stress ⓘ

CHOP↓, 1, eIF2α↓, 1, p‑eIF2α↓, 1, ER Stress↓, 6, HSP70/HSPA5↑, 1, HSP90↑, 2, p‑PERK↓, 1, UPR↓, 1,

Autophagy & Lysosomes ⓘ

Beclin-1↑, 3, LC3B↑, 1, LC3II↑, 2, p62↓, 1,

DNA Damage & Repair ⓘ

DNAdam↓, 1, DNMT1↓, 1, DNMTs↓, 1, p16↓, 1, RAD51↓, 1, TP53↑, 1,

Proliferation, Differentiation & Cell State ⓘ

ERK↑, 1, p‑ERK↑, 2, GSK‐3β↓, 1, Jun↓, 1, KLF4↑, 1, mTOR↓, 1, mTOR↑, 1, p‑mTOR↓, 1, P70S6K↓, 2, PI3K↓, 1, PI3K↑, 1, STAT1↓, 1, STAT3↑, 1, STAT4↓, 1,

Migration ⓘ

AntiAg↑, 1, APP↓, 4, Ca+2↓, 2, mt-Ca+2↓, 1, CD31↑, 2, CDK5↓, 1, LAMs↑, 1, N-cadherin↑, 2, Smad1↑, 1, TGF-β↓, 1, TGF-β1↓, 1, α-SMA↓, 1,

Angiogenesis & Vasculature ⓘ

angioG↑, 2, ATF4↓, 1, VEGF↑, 2,

Barriers & Transport ⓘ

BBB↑, 3,

Immune & Inflammatory Signaling ⓘ

CRP↓, 1, IFN-γ↑, 1, IL10↑, 4, IL17↑, 1, IL1β↓, 2, IL6↓, 2, IL6↑, 1, Inflam↓, 14, JAK2↑, 1, NF-kB↓, 4, Th1 response↓, 1, Th17↓, 1, TNF-α↓, 4,

Synaptic & Neurotransmission ⓘ

5HT↑, 1, AChE↓, 9, BChE?, 1, BChE↓, 3, BDNF↑, 2, MAOA↓, 2, tau?, 1, p‑tau↓, 4,

Protein Aggregation ⓘ

Aβ↓, 8, BACE↓, 3, MAOB↓, 3, PP2A↑, 1,

Drug Metabolism & Resistance ⓘ

BioAv↓, 4, BioAv↑, 5, BioAv↝, 4, Dose↝, 2, eff↑, 4, Half-Life↓, 2, Half-Life↝, 2,

Clinical Biomarkers ⓘ

ALAT↓, 1, ALP↓, 1, AST↓, 1, BG↓, 1, CRP↓, 1, GutMicro↑, 1, IL6↓, 2, IL6↑, 1, TP53↑, 1,

Functional Outcomes ⓘ

cardioP↑, 6, cognitive↑, 8, hepatoP↑, 3, memory↑, 8, Mood↑, 1, motorD↑, 1, neuroP↑, 9, RenoP↑, 3, toxicity↓, 5, toxicity↑, 1,
Total Targets: 144

Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:41  Target#:%  State#:%  Dir#:%
  wNotes=0  sortOrder:rid,rpid

Database Query Results : Berberine, ,

Pathway results for Effect on Cancer / Diseased Cells:

Redox & Oxidative Stress ⓘ

Mitochondria & Bioenergetics ⓘ

Core Metabolism/Glycolysis ⓘ

Cell Death ⓘ

Kinase & Signal Transduction ⓘ

Transcription & Epigenetics ⓘ

Protein Folding & ER Stress ⓘ

Autophagy & Lysosomes ⓘ

DNA Damage & Repair ⓘ

Cell Cycle & Senescence ⓘ

Proliferation, Differentiation & Cell State ⓘ

Migration ⓘ

Angiogenesis & Vasculature ⓘ

Barriers & Transport ⓘ

Immune & Inflammatory Signaling ⓘ

Hormonal & Nuclear Receptors ⓘ

Drug Metabolism & Resistance ⓘ

Clinical Biomarkers ⓘ

Functional Outcomes ⓘ

Pathway results for Effect on Normal Cells:

Redox & Oxidative Stress ⓘ

Metal & Cofactor Biology ⓘ

Mitochondria & Bioenergetics ⓘ

Core Metabolism/Glycolysis ⓘ

Cell Death ⓘ

Transcription & Epigenetics ⓘ

Protein Folding & ER Stress ⓘ

Autophagy & Lysosomes ⓘ

DNA Damage & Repair ⓘ

Proliferation, Differentiation & Cell State ⓘ

Migration ⓘ

Angiogenesis & Vasculature ⓘ

Barriers & Transport ⓘ

Immune & Inflammatory Signaling ⓘ

Synaptic & Neurotransmission ⓘ

Protein Aggregation ⓘ

Drug Metabolism & Resistance ⓘ

Clinical Biomarkers ⓘ

Functional Outcomes ⓘ

Home Page